Ursula A. Matulonis, MD, discusses the impact of PARP inhibitors on ovarian cancer treatment.
Ursula Matulonis, MD
Advertisement
Articles by Ursula Matulonis, MD
Ursula Matulonis, MD, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, discusses two upcoming trials for both platinum-resistant and platinum-sensitive recurrent ovarian cancer.
Advertisement
Latest Updated Articles
An Abundance of PARP Inhibitors are Changing Ovarian Cancer TreatmentPublished: March 10th 2022 | Updated:
Dr. Ursula Matulonis on Phase III Trials Examining Cediranib Plus Olaparib in Ovarian CancerPublished: March 24th 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
